Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

6 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(41.7%)
Phase 3
5(41.7%)
Phase 4
1(8.3%)
Phase 2
1(8.3%)
12Total
Phase 1(5)
Phase 3(5)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT05934890Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Role: lead

NCT04450498Phase 4Completed

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Role: lead

NCT04990544Phase 2Unknown

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Role: collaborator

NCT05313022Phase 1Unknown

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Role: collaborator

NCT04982068Phase 1Unknown

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Role: collaborator

NCT05394012Phase 1Unknown

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Role: lead

NCT05580341Phase 3Unknown

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Role: collaborator

NCT05396573Phase 1Unknown

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Role: lead

NCT04847102Phase 3Unknown

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

Role: lead

NCT02736240Phase 3Completed

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Role: lead

NCT04236960Phase 1Completed

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Role: lead

NCT02285036Phase 3Completed

Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

Role: lead

All 12 trials loaded